JERSEY CITY, N.J., March 08, 2025--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced results from an analysis of the Phase 3 ADORING 3 open-label ...

Organon (OGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Organon (OGN) reported $1.59 billion in revenue for the quarter ended December 2024, representing a year-over-year decline of 0.4%. EPS of $0.90 for the same period compares to $0.88 a year ago.

SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the ...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2024. “In 2024 we achieved our third year of constant ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, which is also under review by the FDA for atopic dermatitis. If it goes ...

Recognising the critical importance of women’s health in driving economic and social development, Organon (Thailand) Company Limited, in collaboration with Kenan Foundation Asia, the Ministry of ...